Document 0575
 DOCN  M9590575
 TI    Use of subcutaneous implantable infusion systems in neoplastic and AIDS
       patients requiring long-term venous access.
 DT    9509
 AU    Dionigi P; Cebrelli T; Jemos V; Minoli L; Gobbi P; Dimitrov G;
       Department of Surgery, University of Pavia, Italy.
 SO    Eur J Surg. 1995 Feb;161(2):137-42. Unique Identifier : AIDSLINE
       MED/95290535
 AB    OBJECTIVE: To evaluate the life span and complication rates of totally
       implantable infusion devices in patients with short bowel syndrome and
       in immunocompromised patients with AIDS, lymphoma, and myeloma who
       required long-term central venous access. DESIGN: Prospective open
       study. SETTING: University hospital, Italy. SUBJECTS: Group I - 5
       patients with short bowel syndrome; group II - 11 patients with AIDS;
       and group III - 15 patients with lymphoma or multiple myeloma (1 of whom
       had 2 devices implanted). MAIN OUTCOME MEASURES: Duration of
       implantation and incidence of catheter-related complications. RESULTS:
       The mean duration/patient of the catheter was 422 days (range 20-1257)
       in group I; 104 days (range 43-262) in group II; and 415 days (range
       62-1280) in group III. There were no catheter related complications in
       the patients in group I (short bowel syndrome). Of the 11 patients with
       AIDS (group II) 4 developed catheter related infections (0.32/100
       catheter days), and 1 developed a thrombotic occlusion. All 5 catheters
       were removed (3 for infection). Of the 15 patients with lymphoma or
       myeloma who had 16 catheters implanted (group III), 1 patient developed
       3 infective episodes (0.05/100 catheter days), 1 catheter migrated and 1
       occluded. All 3 catheters were removed. CONCLUSION: Totally implantable
       infusion systems can safely be used for prolonged periods in
       immunocompromised patients, including those with AIDS if their life
       expectancy is reasonable.
 DE    Acquired Immunodeficiency Syndrome/*THERAPY  Adult  Catheterization,
       Central Venous/ADVERSE EFFECTS/INSTRUMENTATION  *Catheters,
       Indwelling/ADVERSE EFFECTS  Female  Human  Immunocompromised Host
       Infection/ETIOLOGY  *Infusion Pumps, Implantable/ADVERSE EFFECTS  Life
       Expectancy  Long-Term Care  Lymphoma/*THERAPY  Male  Middle Age
       Multiple Myeloma/*THERAPY  Short Bowel Syndrome/*THERAPY  Survival Rate
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).